News

Christina Y. Weng, MD, MBA, shared insights from recent publications on teleretinal screenings for diabetic retinopathy. She will be presenting an overview of these findings at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois during a talk entitled, "The use of teleretinal screening for diabetic retinopathy."

George O. Waring, IV, MD provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster shared data on the the 9-month FDA data of the recently approved excimer laser, the TENEO laser, by Bausch + Lomb.

SLT superior to glaucoma drops as first-line treatment.

In visual field progression results, SLT was superior to ocular drops as first-line treatment for patients with glaucoma

Adam Muzychuck, MD, FRCSC, sat down to discuss his presentation on the defocus curve performance of trifocal IOLs and the outcomes of the near activity vision questionnaire given to patients implanted with the Envy full range of vision IOL at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

In data presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, the two-year study finds patients with advanced disease can recover some vision.

Farhad Hafezi, FARVO, MD, PhD, and colleagues reported on results achieved with phototherapeutic keratectomy-assisted, customised, epi-on corneal crosslinking

Matt Giegengack, MD, explains how injectable corneal endothelial cell therapy can enhance visual acuity and alleviate glare, offering a versatile alternative to current treatments like DMEK.

In an interview with Ophthalmology Times, Quan Dong Nugyen, MD, MSc, discusses ongoing research into Tinlarebant, an investigational drug being studied as a treatment for Stargardt disease in adolescents.

The investigators conducted a study in which they evaluated the retinal structure in patients with ametropic amblyopia and then correlated it with the final visual acuities achieved after 6 months of follow-up using a multimodal imaging approach.

A novel oral therapeutic showed promising results in a Phase 2 study involving 13 subjects

Abdelrahman Elhusseiny, MD, MSc, sat down with David Hutton of Ophthalmology Times to discuss his presentation on the risk of posterior capsular rupture in fellow eyes of cataract surgery at this year's American Academy of Ophthalmology meeting being held in Chicago, Illinois.

Investigators conducted a retrospective clinical database study that covered 12 years to quantify the risk of PCR in the second eye after PCR developed in the first eye during cataract surgery.

Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery

According to data presented in a late-breaking oral presentation at the American Academy of Ophthalmology 2024 Annual Meeting in Chicago.1 efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies.

The study is now expected to be fully enrolled with all 300 patients randomized by the end of 2024.

New research presented at the American Academy of Ophthalmology’s Cornea Subspecialty Day is part of the part of the 8-year Zoster Eye Disease Study.

In the first five months of the program at Henrietta Johnson Medical Center, 26% of patients with images gradable by EyeArt tested positive for either more-than-mild or vision-threatening diabetic retinopathy.

How cell phone use can affect student retention and attention in the classroom.

The research found that, in the classroom, when learning-focused cell phone use increased, social use decreased

How cell phone use can affect student retention and attention in the classroom.

A home self-imaging device can provide ophthalmologists with actionable insight between office visits for AMD

This initiative is supported by a $5 million grant from the Knights Templar Eye Foundation.

Thomas Aaberg Jr, MD sat down to discuss previous presentations by Neurotech at EURETINA and Retina Society as well as upcoming presentations on NT-501 at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

PMC-403 is a novel TIE2-activating antibody with a mechanism that stabilizes pathological, leaky blood vessels.